Premier Inc (NASDAQ:PINC) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Sunday, MarketBeat Ratings reports. The brokerage currently has a $36.00 target price on the stock. Zacks Investment Research‘s price target points to a potential upside of 12.25% from the company’s current price.

According to Zacks, “Premier, Inc. operates as a healthcare alliance. The company brings together hospitals, health systems, physicians and other healthcare providers primarily in the United States. It also maintains clinical, financial and outcomes databases. Premier, Inc. is headquartered in Charlotte, North Carolina. “

Premier (NASDAQ:PINC) traded up 1.17% during midday trading on Friday, hitting $32.07. The stock had a trading volume of 304,317 shares. Premier has a 1-year low of $31.12 and a 1-year high of $39.81. The stock’s 50-day moving average is $33.97 and its 200-day moving average is $35.16. The stock’s market capitalization is $1.40 billion.

Premier (NASDAQ:PINC) last issued its quarterly earnings data on Monday, November 9th. The company reported $0.38 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.37 by $0.01. The company had revenue of $270.80 million for the quarter, compared to the consensus estimate of $265.69 million. During the same quarter last year, the business earned $0.33 earnings per share. Premier’s revenue was up 18.1% compared to the same quarter last year. On average, equities research analysts anticipate that Premier will post $1.60 EPS for the current fiscal year.

In related news, Director Stephen R. D’arcy bought 2,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 17th. The shares were bought at an average price of $34.32 per share, with a total value of $68,640.00. Following the completion of the transaction, the director now directly owns 5,408 shares in the company, valued at $185,602.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

A number of other equities research analysts also recently weighed in on the company. Avondale Partners began coverage on Premier in a report on Wednesday, October 21st. They issued an “outperform” rating and a $38.00 target price for the company. Oppenheimer reiterated a “buy” rating and issued a $41.00 target price on shares of Premier in a report on Wednesday, October 7th. Canaccord Genuity reiterated a “buy” rating and issued a $43.00 target price on shares of Premier in a report on Friday, October 2nd. William Blair reiterated an “outperform” rating on shares of Premier in a report on Monday, October 12th. Finally, Evercore ISI lifted their target price on Premier from $37.00 to $38.50 and gave the stock a “buy” rating in a report on Monday, November 2nd. One investment analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $41.23.

Premier, Inc. is a healthcare improvement company. The Company is uniting an alliance of approximately 3,600 United States hospitals and approximately 120,000 other providers to transform healthcare. The Company operates healthcare group purchasing organizations and also provides integrated data and analytics, supply chain solutions, advisory services, performance improvement collaborative and other services. The Company plays a role in the healthcare industry, collaborating with members to co-develop long-term innovations that reinvent and improve the way care is delivered to patients nationwide.

12 Month Chart for NASDAQ:PINC

Get a free copy of the Zacks research report on Premier (PINC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Premier Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Premier Inc and related companies with MarketBeat.com's FREE daily email newsletter.